Table 1.
Demographic and Baseline Characteristics of 304 Patients, ANRS CO3, Aquitaine Cohort
| Baseline Parameter | Total (N = 304) |
|---|---|
| Median age, years (IQR) | 47 (39–54) |
| Gender, % | |
| Male | 73.4 |
| Female | 26.3 |
| Transgender | 0.3 |
| Transmission group, n (%) | |
| MSM | 133 (43.8) |
| Heterosexual | 117 (38.5) |
| Intravenous drug use | 22 (7.2) |
| Other | 32 (10.5) |
| AIDS clinical stage,a n (%) | |
| A | 212 (69.7) |
| B | 57 (18.8) |
| C | 35 (11.5) |
| Tobacco consumption, n (%) | |
| Yes | 119 (40.8) |
| No | 173 (59.2) |
| Missing data | 12 (3.9) |
| HT, n (%) | |
| Yes | 125 (41.1) |
| Lipid parameters, median mg/dL (IQR) | |
| TC | 200 (170–227) |
| LDL | 124 (97–148) |
| HDL | 47 (39–58) |
| Triglycerides | 119 (81–178) |
| TC/HDL ratio | 4.1 (3.3–5.1) |
| Creatinine clearance – MDRD (mL/min/1.73 m2), median (IQR), N = 299 | 105 (92–120) |
| CD4+ cell count (cells/mm3), median (IQR) | 602 (462–788) |
| Nadir CD4+ cell count (cells/mm3), median (IQR) | 252 (152–343) |
| Time since first antiretroviral medication (years), median (IQR) | 7.7 (3.7–12.7) |
| Time since HIV plasma viral load <50 copies/mL (years), median (IQR) | 4.9 (2.1–8.2) |
| cART at switch, n (%) | |
| cART containing TDF | 231 (76.0) |
| 2 NRTI + 1 PI/r | 131 (43.1) |
| 2 NRTI + 1 NNRTI | 108 (35.5) |
| With EFV | 86 (28.3) |
| Without EFV | 22 (7.2) |
| 2 NRTI + 1 INI | 29 (9.5) |
| Other third agent | 36 (11.8) |
| Switch reason | |
| cART simplification | 224 (73.7) |
| Adherence improvement | 89 (29.3) |
| Laboratory abnormalities | 101 (33.2) |
| Dyslipidemiab | 75 (24.7) |
| Other | 26 (8.6) |
| Previous ARV side effects | 116 (38.2) |
| Neurological disorders | 72 (23.7) |
| Patients previously on EFV | 59 (19.4) |
| Patients without EFV | 13 (4.3) |
| Digestive disorders | 25 (8.2) |
| Other side effectsc | 19 (6.2) |
| Other reasonsd | 28 (9.2) |
Abbreviations: AIDS, acquired immune deficiency syndrome; ANRS, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales; ARV, antiretroviral; cART, combined antiretroviral therapy; EFV, efavirenz; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HT, arterial hypertension; INI, integrase inhibitor; IQR, interquartile range; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; TC, total cholesterol; TDF, tenofovir disoproxil fumarate; TG, triglycerides.
a AIDS stage according to the US Centers for Disease Control and Prevention classification.
b TC >2.0 g/L and/or TG >1.5 g/L and/or prescription of lipid-lowering agents.
c Other side effects: dermatological, gynecological, myalgia, urolithiasis, lypodystrophia.
d Other reasons to switch: statin intolerance, post childbirth, cardiovascular risk factors, weight gain, drug interactions.